Beatson West of Scotland Cancer Centre, Glasgow

The Beatson West of Scotland Cancer Centre is based on the Gartnavel hospital campus in Glasgow and is operated by NHS Greater Glasgow and Clyde. Its current purpose-built centre opened in 2007, continuing a longer history of cancer care in Glasgow. It provides specialist services within Scotland’s publicly funded health system.

The Beatson is widely described as one of the largest cancer centres in the UK. This describes its scale and regional responsibilities, not a ranking of quality or outcomes. Its remit includes radiotherapy and systemic anticancer treatment for a substantial regional population, with patients referred from hospitals across the west of Scotland.

Cancer care is organised through multidisciplinary teams that bring together expertise relevant to each diagnosis. Investigations, surgery, drug treatment, radiotherapy and follow-up may take place at different hospitals within the regional network. Patients should therefore distinguish care delivered at the Beatson itself from services provided by partner teams elsewhere.

The centre also participates in clinical research and has links with the Cancer Research UK Scotland Institute. These connections support research into cancer biology and treatment, but do not mean that every laboratory discovery is available clinically. Routine care, clinical trials and early-stage research have different access requirements.

The centre’s programmes include breast, lung, colorectal and prostate cancers. Care may involve treatment intended to cure cancer, reduce recurrence risk, control advanced disease or relieve symptoms. For breast and prostate cancers, hormone-based treatments can be relevant alongside other modalities; for lung and colorectal cancers, tumour testing may help identify suitable drug options. The appropriate pathway depends on the specific diagnosis and clinical circumstances.

Blood cancers are also part of the relevant specialist care network, with haematology expertise important for conditions such as lymphoma, leukaemia and myeloma. Patients should confirm which team and hospital would manage their particular condition, especially if intensive inpatient treatment or a highly specialised procedure is being considered. A listed cancer specialty does not imply that every subtype, age group or treatment is managed at the same site.

Radiotherapy is a core Beatson service. It may be recommended alone, alongside drug treatment, before or after surgery, or to relieve symptoms. Planning usually requires a dedicated assessment and imaging. The technique, number of appointments and suitability for previous radiotherapy patients are determined individually; international patients should not book travel around an assumed treatment schedule.

Systemic treatments include chemotherapy, immunotherapy and targeted therapy where clinically indicated and available within the applicable care pathway. Hormone therapy is relevant to some cancers. Decisions may depend on pathology review, molecular results, organ function and previous treatments. A medicine being licensed internationally does not automatically mean it is routinely available through an NHS service or appropriate for a particular patient.

Surgery is part of the wider regional cancer pathway rather than a service patients should assume is performed within the Beatson oncology centre. Surgical assessment and operations are arranged through the appropriate specialist hospital teams. Patients needing combined treatment should ask who coordinates the sequence and whether appointments involve multiple sites.

Supportive and palliative care can accompany anticancer treatment, including symptom management and help with treatment effects. Clinical trials may offer additional treatment approaches, but these remain subject to a research protocol. None of these modalities is universally suitable, and assessment may lead to a recommendation for care closer to home.

The Beatson has an established clinical trials portfolio involving different cancer types and treatment approaches. Around 120 active oncology trials is an indicative figure provided for this profile, not an independently verified live total. Studies open and close, and an active study may be following existing participants rather than recruiting new ones. Current availability must be checked with the relevant clinical team.

International patients generally need specialist review before a trial team can assess eligibility. Criteria may include cancer subtype, biomarkers, previous treatments, fitness and laboratory results. Overseas residence can also raise practical issues around funding, repeated visits, emergency care and follow-up. Trial participation is not guaranteed, and research funding does not necessarily cover all healthcare or travel expenses. Patients should request information about a specific recruiting study rather than travel in anticipation of a place.

Begin by asking NHS Greater Glasgow and Clyde whether the relevant service can consider an overseas referral and which administrative route applies. Provide a concise clinical summary and establish how records can be transferred securely. Acceptance for assessment is distinct from acceptance for treatment, and neither should be assumed from the centre’s public information.

Before making non-refundable arrangements, obtain written clarification of the proposed assessment, funding responsibilities and likely attendance pattern. Ask whether treatment could safely be delivered locally with specialist advice instead. If Glasgow care is agreed, plan for possible schedule changes, treatment complications and follow-up after returning home. Your home oncology team should remain involved in continuity of care.

Contact details below come from the hospital's own published international patient information.

Location: Glasgow, United Kingdom

Email: No public international e-mail address is published; use the website enquiry form.

Phone: +44 141 301 7000

Website: https://www.nhsggc.scot

Languages supported: English

Remote second opinion: Not advertised

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.